INTRODUCTION
Chimeric antigen receptor (CAR) comprises an extracellular antigenbinding domain combined with an intracellular signal transduction domain. 1 The first-generation CAR-transduced T (CAR-T) cells that have CD3z as a signal transduction domain of the CAR often become anergic and fail to elicit a potent immune response. 2 The second-and third-generation CAR-T cells have been developed by adding one and two co-stimulatory signal domains (CSSDs) in the CAR, respectively. 1 These CAR molecules with the modular structure have been shown to successfully mimic the T cell receptor-mediated signal transduction upon cognate antigen stimulation, leading to proliferation and activation of CAR-T cells. 3 The immunotherapy using CD19-targeted CAR-T cells demonstrated remarkable efficacy against B cell malignancy. 4 To expand the possibilities to various clinical applications, 5 it may be necessary to further improve CAR-T cell efficacy. Signaling assumed by the CSSD derived from co-stimulatory molecules is known be a key event for exhibiting potent CAR-T cell efficacy. 1 However, the effects of CSSDs on CAR-T cell functions and characteristics are still largely unknown.
Co-stimulatory molecules can be classified into two major families: the CD28 family, including CD28 and inducible T cell co-stimulator (ICOS), and the tumor necrosis factor (TNF) receptor superfamily (TNFRSF), including 4-1BB and herpes virus entry mediator (HVEM). So far, the CSSD derived from CD28 or 4-1BB has commonly been used to construct CARs. 6 A previous study showed that the second-generation CAR-T cells with a 4-1BB-derived CSSD persisted for more than 6 months in the blood of most patients, whereas the CAR-T cells with a CD28-derived CSSD became mostly undetectable after 3 months. 7 Additionally, 4-1BB co-stimulation induced enhanced differentiation to the central memory subset with increased in vitro persistence. 8 4-1BB co-stimulation has also been shown to increase mitochondrial biogenesis and oxidative metabolism for energy production and avert tonic signaling-induced T cell exhaustion. 9 Therefore, the CSSD derived from the TNFRSF appears to function better than the one from the CD28 family in the context of second-generation CAR-T cells.
Accumulating reports have suggested potential roles of HVEM, another member of the TNFRSF, in effector function and memory development of CD8 + T cells. For example, HVEM deficiency in CD8 + T cells has been shown to profoundly impair effector CD8 + T cell survival and development of protective immunological memory. 10 An interaction between HVEM expressed on CD8 + T cells and B-and T-lymphocyte attenuator has also been reported to promote survival and immunological memory generation in response to bacterial infection. 11 Additionally, tumor cells that express anti-HVEM single-chain antibody induce a potent proliferation and cytokine production of co-cultured T cells. 12 These findings have indicated that HVEM serves as a potent co-stimulatory molecule in T cells, suggesting that the CSSD derived from HVEM may also be useful in the context of CAR-T cells.
We generated the HIV Env-targeting CAR-T cells with CSSDs derived from CD28, 4-1BB, and HVEM, and we examined their effector functions using HIV Env-expressing target cells. The CAR-T cells with the HVEM-derived CSSD exhibited higher effector functions than those with CD28-and 4-1BB-derived CSSDs. Further analyses showed that the CAR-T cells with the HVEM-derived CSSD efficiently induced both central and effector memory subsets with significantly higher glycolysis and mitochondrial respiration while they averted exhaustion. Therefore, we demonstrate that the CAR-T cells with the HVEM-derived CSSD exhibit high functional potency.
RESULTS

CAR with the HVEM-Derived CSSD Is Efficiently Expressed in a Human T Cell Line
An sCD4, corresponding to 1-178 amino acids of human CD4, was reported to selectively target HIV-infected cells through binding to an HIV Env. 13 To generate HIV Env-targeting CAR-T cells, we constructed lentiviral vectors expressing the CAR in combination with CSSDs derived from CD28, 4-1BB, and HVEM ( Figure 1A ). Flow cytometric analysis indicated that the transduction rates of Jurkat E6.1 cells with different lentiviral vectors were similar to each other ( Figure S1 ). On the other hand, the levels of CAR expression on the cell surface of GFP + cells differed considerably ( Figure 1B ), and they were the highest on the CAR-T cells with the HVEM-derived CSSD ( Figure 1C ). Western blot analysis also revealed that amounts of the CAR with the HVEM-derived CSSD were larger than those with CD28-and 4-1BB-derived CSSDs in whole-cell lysates ( Figure 1D ). Figure 2A) . Also, measurement of interleukin-2 (IL-2) in the culture supernatants showed that IL-2 secretion by the CAR-transduced Jurkat E6.1 cells was induced upon co-cultivation with CHO-Env-GFP cells, but not with control CHO-GFP cells ( Figure 2B ). These data demonstrated that human T cells transduced with the CAR-expressing vectors constructed in this study were specifically activated upon cognate antigen stimulation. Linear regression analysis demonstrated that the percentages of activated T cells upon cognate antigen stimulation and IL-2 secretion were correlated with the levels of CAR expression on the cell surface ( Figures 2C and 2D ).
Human Primary T Cell-Derived CAR-T Cells with the HVEM-Derived CSSD Exhibit Potent Effector Functions
To compare the CAR-T cells with different CSSDs in more detail, we transduced human primary CD8 + with the CAR-expressing lentiviral vectors, and we analyzed for their effector functions. Similar to the observations in Jurkat E6.1 cells ( Figures 1B-1D ), the CAR expression levels on the cell surface and in whole-cell lysate were the highest for the CAR-T cells with the HVEM-derived CSSD and the lowest for those with the CD28-derived CSSD ( Figures 3A-3C and S3). We also compared the effector functions of the CAR-T cells with different CSSDs. Although all of the three CAR-T cells led to antigen-specific cytotoxic activities against HIV Env-expressing target cells, the CAR-T cell with the HVEM-derived CSSD exhibited the highest activity ( Figure 3D ). Similarly, the highest levels of cytokines, such as IL-2, TNF-a, and interferon (IFN)-g, were secreted from the CAR-T cells with the HVEM-derived CSSD compared to the other CAR-T cells tested in this study ( Figure 3E ). Comparable with the observations in Jurkat E6.1 cells ( Figures 2C and 2D ), effector functions of the CAR-T cells measured by cytotoxic activities and cytokine secretions were correlated with the levels of CAR expression on the cell surface ( Figures 3F and S4) . Thus, the CAR-T cells with the HVEM-derived CSSD appeared to be potent. 16 We thus analyzed proportions of 
CAR-T Cells with the HVEM-Derived CSSD Avert T Cell Exhaustion
Prolonged stimulation of T cells has been known to cause exhaustion characterized by decreased proliferation, lowered levels of cytokine production, high rates of apoptosis, and expression of inhibitory receptors, such as programmed cell death 1 (PD-1) and lymphocyte activation gene 3 (LAG-3). 17, 18 To determine the effect of CSSDs on T cell exhaustion, we examined the percentages of PD-1 + , LAG-3 + , and PD-1 + /LAG-3 + exhausted T cell populations ( Figures   5A and 5B). The results showed that the CAR-T cells with the CD28-derived CSSD contained relatively large percentages of exhausted T cells, whereas those with the 4-1BB-derived CSSD contained significantly lower percentages of exhausted T cells at days 9 and 16 after transduction ( Figures 5C and 5D ). The LAG-3 + population, but not the PD-1 + /LAG3 + population, was induced in the CAR-T cells with the HVEM-derived CSSD compared to control T cells at day 9 after transduction ( Figure 5C ). Moreover, the CAR-T cells with the HVEM-derived CSSD contained the lowest percentage of exhausted T cells among the CAR-T cells tested in this study at day 16 after transduction ( Figure 5D ). Interestingly, the percentages of PD-1 + and LAG-3 + cells were larger and smaller, respectively, for the CAR-T cells with the HVEM-derived CSSD than those with the 4-1BB-derived CSSD at day 16 after transduction ( Figure 5D ). Taken together, these data suggested that the CAR-T cells with the HVEM-derived CSSD averted T cell exhaustion.
CAR-T Cells with the HVEM-Derived CSSD Exhibit Reprogrammed Energy Metabolism
It has recently been shown that T cell exhaustion was accompanied by deficient energy metabolism. 19, 20 Thus, we compared metabolic states of the CAR-T cells with different CSSDs at basal condition and following the serial addition of reagents to analyze relative contribution of mitochondrial and non-mitochondrial mechanisms of oxygen consumption ( Figure 6A ). Mitochondrial respiration and glycolysis can be measured by oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), respectively. The CAR-T cells with the HVEM-derived CSSD showed the highest level of basal OCR, followed by those with the 4-1BB-derived CSSD and the control T cells; those with the CD28-derived CSSD showed the lowest level of basal OCR ( Figure 6B ). We also measured ATP-linked respiration by adding an ATP synthase inhibitor oligomycin and maximal OCR levels by adding carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP; uncoupling of oxygen consumption from ATP production) ( Figure 6A ). The results indicated that ATP-linked respiration and maximal OCR levels in the different CAR-T cells were similarly elevated as basal OCR levels ( Figures 6C and 6D) . Interestingly, basal ECAR was significantly increased only for the CAR-T cells with the HVEM-derived CSSD ( Figure 6E ). These data indicated that the CAR-T cells with the CD28-derived CSSD exhibited a low-energy state, whereas those with the 4-1BB-derived CSSD induced higher mitochondrial respiration. Moreover, the CAR-T cells with the HVEM-derived CSSD induced enhanced glycolysis as well. These results suggested that the HVEM-derived CSSD could lead to reprogramming of energy metabolism.
DISCUSSION
We developed lentiviral vectors expressing the CAR consisting of sCD4 as an antigen recognition domain combined with CSSDs derived from CD28, 4-1BB, and HVEM. Transducing the human T cell line and primary T cells with these vectors, we demonstrated that the CSSD in CAR construct was a crucial determinant for the levels of CAR expression on the cell surface, which appeared to be correlated with the activities and effector functions of the CAR-T cells. It was also shown in this study that T cell exhaustion, energy metabolism, and induction of the memory T cell subsets were also affected by the CSSD in CAR constructs. Among the CSSDs examined in this study, the HVEM-derived CSSD led to the highest level of CAR expression, most potent effector functions of CAR-T cells, evasion of exhaustion, and balanced induction of both central and effector memory T cell subsets, associated with elevated glycolysis and mitochondrial respiration. The results of this study suggest that the HVEM-derived CSSD may be useful for generating effective CAR-T cells in a certain context. It is unknown yet how the CSSD controls the level of CAR expression on the cell surface. Since amounts of CAR molecules in whole-cell lysate were correlated to the level of the cell surface expression, CAR synthesis rather than trafficking might be affected by the CSSD. Among other possibilities, different CSSDs might activate different signaling pathways, resulting in distinct levels of gene expression. For example, CD28-mediated co-stimulation induces the phosphoinositide 3-kinase (PI3K)-Akt pathway, whereas 4-1BB-mediated costimulation primarily activates c-Jun N-terminal kinase (JNK) and p38 through TNFR-associated factors. 21, 22 It has also been shown that 4-1BB and HVEM are capable of activating alternative nuclear factor kB (NF-kB) pathways. 23 These differences in signaling pathways may affect the CAR expression at a transcriptional or translational level. 24 Antigen-independent tonic signaling during ex vivo expansion has been shown to cause exhaustion of the CAR-T cells with the CD28-derived CSSD, whereas those with the 4-1BB-derived CSSD are relatively refractory to exhaustion. 9 Our studies not only confirmed these observations but also demonstrated that the HVEM-derived CSSD could avert CAR-T cell exhaustion. In addition, our data suggested that CSSDs in CAR constructs could affect the degrees of T cell exhaustion through differential effects on the inhibitory receptor expression ( Figure 5B ). Since 4-1BB and HVEM are classified in the TNFRSF, it is possible that the CSSD derived from the TNFRSF, but not from the CD28 family, might allow CAR-T cells to avoid exhaustion.
Mitochondrial dynamics have been suggested to control T cell fate through metabolic programming. 25 In addition, 4-1BB-mediated costimulation has been reported to enhance mitochondrial respiration with increased central memory subsets. 8 Our results were compatible with these previous studies, and they also demonstrated that the HVEM-derived CSSD enhanced both glycolysis and mitochondrial respiration and yielded relatively low levels of T cell exhaustion as well. It has also been shown that various T cell subsets require distinct metabolic programs to support their function. [26] [27] [28] Our data suggested that co-stimulation signals impacted differentiation of the CAR-T cells to central and effector memory T cell subsets and that the HVEMderived CSSD induced efficient and balanced differentiation. Different co-stimulatory signals are likely to affect metabolic programs in distinct manners to differentiate specific memory T cell subsets.
Development of new anti-HIV drugs and progress in anti-retroviral therapy (ART) dramatically improved the prognosis of HIV-infected patients. However, it has not been successful for ART to completely eliminate HIV from the patient's body due to persistence of latently infected cells. To achieve this goal, the so-called "shock-and-kill" approach, which combines pharmacological reactivation of the latently infected cells and following immunotherapies with HIV-specific cytotoxic T lymphocytes (CTLs) or broadly neutralizing antibodies (bNAbs), has been proposed. 29 In this protocol, CD4-based CAR-T cells targeting the conserved region of HIV-1 Env might be more useful than T cell receptor (TCR)-based or bNAb-based CAR-T cells, which fail to recognize the antigens with escape mutations. In fact, a recent study reported promising results of the CAR-T cells harboring a 4-1BB-derived CSSD in the in vitro and in vivo models of HIV treatment. 30 The results of our study strongly suggest that the CD4-based CAR-T cells with the HVEM-derived CSSD, which showed more potent effector functions than those with the CD28-and 4-1BB-derived CSSDs, may also be a useful tool for the shockand-kill treatment of HIV infection.
Our results showed that CAR expression levels were clearly associated with effector functions in Jurkat T cells (Figures 2C and 2D ) and CD8 T cells (Figures 3F and S4 ) under similar transduction efficiencies ( Figures S1 and S3 ), suggesting that CAR expression level could be the major contributor for the higher effector functions. Since CAR expression was different among CAR-T cells with different CSSDs, it is very hard to determine whether the CAR expression or the biological functions of CSSDs mainly affect CAR-T cell effector functions and characteristics using this experimental system. However, the biological functions of CSSDs might affect CAR-T cell characteristics, such as T cell exhaustion and memory phenotype, because the type of CSSD, but not CAR expression level, was associated with these CAR-T cell characteristics (Figures 4 and 5) .
To further determine this issue, adjusting CAR expression levels in CAR-T cells with different CSSDs may be necessary in future studies using the appropriate experimental system. In addition, while our data indicated the usefulness of the HVEM-derived CSSD in the context of CAR with sCD4 as an antigen-binding domain, it is unknown yet whether the HVEM-derived CSSD is universally versatile. Further studies will be necessary to examine the effects of the HVEM-derived CSSD on activities and functions of CAR-T cells with various antigen specificities. Also, the CD4-based CAR-T cells have been shown to have no potential toxicities in a humanized mouse model 31 and clinical trials. 32 However, it may also be necessary to test, in the future, the potential toxicities of the CD4-based CAR-T cells with the HVEMderived CSSD, because they secreted a relatively larger amount of cytokines than those with the CD28-and 4-1BB-derived CSSDs.
In summary, our results demonstrate that the CSSD in CAR is a crucial determinant for effector functions and characteristics of CAR-T cells, indicating that the CSSD in CAR is important for designing more potent CAR-T cells. Moreover, the HVEM-derived CAR-T cells may be a promising candidate for generating effective CAR-T cells.
MATERIALS AND METHODS
Study Approval
This study was conducted according to the principles of the Declaration of Helsinki and with the approval of the Scientific Ethics Committee of the Dokkyo Medical University. Written informed consent was obtained from all subjects after oral explanation of this study.
Cell Culture
The culture media, minimum essential medium (MEM), DMEM, and RPMI (Thermo Fisher Scientific, Waltham, MA), were supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific), 2 mM glutamine (Thermo Fisher Scientific), 10 U/mL penicillin, and 10 mg/mL streptomycin (Thermo Fisher Scientific) and named shortly M10, D10, and R10, respectively. CHO cells and their transfectants were maintained in M10 supplemented with nonessential amino acid (M10-NEAA). 293FT cells were cultured in D10, and Jurkat E6.1 cells, obtained from European Collection of Authenticated Cell Cultures through DS Pharma, were maintained in R10. Human peripheral blood mononuclear cells (PBMCs) from healthy donors were prepared by Ficoll-Paque (GE Healthcare Life Sciences, Pittsburgh, PA) density gradient and cultured in AIM-V (Thermo Fisher Scientific) supplemented with 5% FBS and 10 mM HEPES (shortly, complete AIM-V) overnight to remove plasticadherent monocytes. Monocyte-depleted PBMCs were used for transduction experiments. All cells were grown at 37 C with 5% CO 2 .
Vector Constructions
To introduce multiple restriction enzyme sites, a DNA linker was introduced into lentiviral vector plasmid pTK643-CMV-IRES-GFP/blastcidine (BSD). The DNA linker containing XbaI-XhoIBsiWI-BstBI-BamHI restriction enzyme sites was made by incubating two oligonucleotides, L1 (5 0 -CTAGACTCGAGCGTACGTTCGA AG-3 0 ) and L2 (5 0 -GATCCTTCGAACGTACGCTCGAGT-3 0 ), at a molar ratio of 1:1 at 70 C for 10 min and left at room temperature for 2 h. The linker DNA was inserted into XbaI/BamHI-digested pTK643-CMV-IRES-GFP/BSD (resulting in pTK643-CMV-MCS-IRES-GFP/BSD).
For making the sCD4-encoding DNA fragment, total RNA extracted from Jurkat E6.1 cells by ISOGEN (Nippon Gene, Tokyo, Japan) was used for cDNA synthesis with ReverTra Ace (Toyobo, Osaka, Japan), according to the manufacturer's instructions. The sCD4 DNA fragment containing XbaI/EcoRI sites was amplified using KOD-FX (Toyobo) with the following primers: sCD4 forward, 5 0 -GAATCTA GAGCCACCATGAACCGGGGAGTC-3 0 ; and sCD4 reverse, 5 0 -GATCTTGAATTCAGCTAGCACCACGATGTC-3 0 . Purified DNA fragment was incubated with Ampli Taq (Thermo Fisher Scientific, Waltham, MA) at 72 C for 10 min to add A tails. The A-tailed DNA fragment was ligated into pGEM-T easy vector (Promega, Madison, WI). The sequence was verified with BigDye Terminator version (v.)3.1 Cycle Sequencing Kit (Thermo Fisher Scientific).
The cDNA fragments encoding CSSDs derived from CD28, 4-1BB, and HVEM were artificially synthesized by GenScript (Piscataway, NJ). To make sCD4-CAR-expressing lentiviral vectors, the XbaI/EcoRI-digested sCD4 DNA fragment and each of the EcoRI/ BamHI-digested CSSD DNA fragments were ligated into XbaI/ BamHI-digested pTK643-EF1a-IRES-GFP/BSD.
For making the HIV Env-(NL4-3 strain) expressing lentiviral vector plasmid, XbaI/XhoI-digested pRE11-NL43, kindly provided by Dr. Noriaki Hosoya, 33 was ligated into XbaI/XhoI-digested pTK643-
CMV-MCS-IRES-GFP/BSD.
Recombinant Lentivirus Production
Recombinant lentivirus was produced as previously described 34 with some modification. Briefly, 293FT cells were cultured on a collagencoated 10-cm dish (Iwaki, Shizuoka, Japan) with 80%-90% confluency. The culture medium was replaced to D10 containing 25 mM chloroquine (Sigma, Darmstadt, Germany) without antibiotics. Regarding vectors packed with DNRF, the following plasmid amounts were used: 15 mg lentiviral vector plasmid, 10 mg DNRF, and 5 mg pMD.G. The plasmids were co-transfected into 293FT cells with polyethyleneimine (PEI) MAX (Polysciences, Warrington, PA) at a DNA-to-PEI ratio of 2:1. The supernatant was replaced with D10 containing 5 mM sodium butylate (Wako Pure Chemicals Industries, Osaka, Japan) and 10 mM forskolin (Tokyo Chemical Industry, Tokyo, Japan). The culture supernatants containing recombinant lentiviruses were harvested at 48 h after transfection and cleared by centrifugation and 0.45-mm filtration (Millipore, Burlington, MA). The recombinant lentiviruses were concentrated by high-speed centrifugation at 18,000 rpm for 3 h using Himac CR21N (Hitachi Koki, Tokyo, Japan). The lentiviral titers were measured on HeLa cells based on the percentage of GFP-positive cells by flow cytometry.
Transduction with Lentiviral Vectors
The recombinant lentivirus-containing supernatant was used to transduce CAR and GFP genes into Jurkat E6.1 cells and HIV Env gene into CHO cells, respectively. Briefly, 2 million Jurkat E6.1 cells or semi-confluent CHO cells in a 6-well plate were exposed to 1 mL unconcentrated lentivirus-containing supernatant in the presence of polybrane at 8 mg/mL. The cells were centrifuged at 5,500 rpm for 3 h at 22 C to enhance viral infection. After removal of the supernatant, the cells were cultured at 37 C in a CO 2 incubator for 48 h. The culture medium was replaced with the media supplemented with 10 mg/mL BSD. Thereafter, transduced cells were maintained in the media with 10 mg/mL BSD until the following assays were performed.
Human primary CD8 T cells were isolated from monocyte-depleted PBMCs with anti-human CD3-allophycocyanin (APC), CD4-phycierythrin (PE), and CD8-PE/Cy7 antibodies (all from BioLegend, San Diego, CA) by cell sorting on a FACS Aria II (BD Biosciences, Franklin Lakes, NJ), and they routinely achieved >95% purity. The purified CD8 T cells were activated with anti-CD3/CD28 beads (Thermo Fisher Scientific) at a bead-to-cell ratio of 3:1 in complete AIM-V supplemented with 40 U/mL recombinant human IL-2 (obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, from Dr. Maurice Gately, Hoffmann-La Roche) for 3 days. After removal of the anti-CD3/CD28 beads, activated CD8 T cells were transduced with concentrated recombinant lentivirus on days 3 and 4 using Retronectin-(Takara Bio, Shiga, Japan) coated plates, according to the manufacturer's instructions. The cells transduced only with GFP were used as a control. Thereafter, the cells were cultured for 16 days with fresh media containing 300 U/mL IL-2 replenished every 2-3 days. Successfully transduced GFP + cells were sorted at 16 days after the initial anti-CD3/CD28 bead stimulation for energy metabolism analysis.
Flow Cytometry
Antibodies used in flow cytometry were obtained from BioLegend otherwise indicated. CAR expression on the transduced Jurkat E6.1 cells was analyzed with anti-c-myc tag antibody (Santa Cruz Biotechnology, Dallas, TX), followed by anti-mouse immunogloburins (Igs)-PE antibody (Agilent Technologies, Santa Clara, CA). Activation of the CAR-transduced Jurkat E6.1 cells in the co-culture assay was analyzed with anti-human CD3-APC antibody and CD69-PE antibody (see Figure S1 for gating strategy). CAR expression on CAR-transduced primary CD8 + T cells was analyzed with biotinylated anti-c-myc tag antibody followed by streptavidin-PE (Tonbo Biosciences, San Diego, CA). For normalizing CAR expression by GFP expression, we divided the mean fluorescence intensity (MFI) of CAR by the MFI of GFP. This value was represented as normalized CAR expression. Exhaustion of the CAR-T cells was analyzed with anti-human PD-1-APC antibody and anti-human LAG-3-PE/Cy7 antibody (Thermo Fisher Scientific). Memory phenotypes of the CAR-T cells were analyzed with CD45RO-PE, CD8-PE-Cy7, and CCR7-APC. The centrifuged cells were resuspended with antibody diluted in fluorescence-activated cell sorting (FACS) buffer (PBS containing 2% FBS and 0.02% sodium azide) and incubated on ice for 30 min. After washing with ice-cold FACS buffer, the cells were fixed with 1% paraformaldehyde in PBS and analyzed with a FACS Calibur (BD Biosciences).
Western Blot
Cells ( were seeded in each well of a 96-well flat-bottom plate. The CAR-T cells were added at different effector-to-target ratios (see also in the figure legend) and co-cultured in phenol red-free R10 with NEAA. After overnight incubation, the cell-free supernatant was collected by centrifugation. Lactate dehydrogenase release in the supernatant was assayed using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). The cytotoxicity (% lysis) was calculated according to the manufacturer's instructions. In cases of unequal percentages of CAR-transduced cells in the cultures, untransduced T cells were added to ensure that both the number of CAR + T cells and the total number of T cells remained consistent across the CAR-T cell groups. Collected supernatants were also used to determine IL-2, TNF-a, and IFN-g secretion using human IL-2, TNF-a, and IFN-g ELISA MAX Deluxe (all from BioLegend), according to the manufacturer's instructions.
Analysis of Energy Metabolism
Mitochondrial function of the CAR-T cells was analyzed with an extracellular flux analyzer XFp (Agilent Technologies, Santa Clara, CA). Each well of the cell culture microplate was coated with CellTak (BD Biosciences), according to the manufacturer's instructions. To assay mitochondrial function, the sorted CAR-T cells without further culture were resuspended in XF RPMI medium supplemented with 5.5 mM Glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate, and they were seeded at 3 Â 10 5 cells/well. The plate was centrifuged at 200 Â g for 1 min and incubated at 37 C in a non-CO 2 incubator for 30-60 min. During incubation, the instrument XFp and its assay cartridges were calibrated according to the manufacturer's instructions. OCRs were measured under basal conditions and following treatment with 1 mM oligomycin (an inhibitor of ATP synthase), 1 mM FCCP (uncoupling of oxygen consumption from ATP production), and 1 mM rotenone and antimycin A (inhibitor for complexes I and III of the electron transport chain, respectively) (XFp Cell Mito Stress Kit, Agilent Technologies). Four measurements of basal condition and after each treatment were performed. ATP-linked respiration was defined as (last rate measurement before oligomycin addition) À (minimum rate measurement after oligomycin addition). Maximal OCR was measured after FCCP treatment.
Statistics
Statistical analysis was described previously. 35, 36 Unpaired one-way or two-way ANOVA with Bonferroni multiple comparison test and linear regression analysis were performed, and R 2 value was calculated using GraphPad Prism (GraphPad, San Diego, CA). A p value < 0.05 was considered statistically significant.
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